Eutropics Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Jul 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Method for predicting cancer sensitivity (US 11,656,230) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due Dec 9, 2026The maintenance fee for Compositions and methods useful for treating diseases (US 9,051,305) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Methods and compositions useful for treating diseases involving Bcl-2 family proteins with isoquinoline and quinoline derivatives (US 10,413,549) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Methods for determining chemosensitivity and chemotoxicity (US 10,640,803) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,755 | Antibodies specific to heterodimers of Bcl-2 family and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,271 | 2,2'-Biphenazine Compounds and Methods Useful for Treating Disease In force · High confidence | In force | High confidence | |
| US 9,351,971 | Substituted 2,2′-biphenazines for treating diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,051,305 | Compositions and methods useful for treating diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,345,700 | Compositions and methods useful for treating diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,360,473 | Assay system to identify therapeutic agents In force · From the USPTO record | In force | From the USPTO record | |
| US 10,413,549 | Methods and compositions useful for treating diseases involving Bcl-2 family proteins with isoquinoline and quinoline derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 10,640,803 | Methods for determining chemosensitivity and chemotoxicity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,656,230 | Method for predicting cancer sensitivity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,519,015 | Methods for determining chemosensitivity and chemotoxicity In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 9 no status recorded